Media
A Fresh Approach to Diabetes
尊凯实业
Mar 11, 2025
277
Dorzagliatin was included in China's National Reimbursement Drug List (NRDL) at the end of 2023. The time reported in the article is 2022, which is incorrect.
Next：
Interview of Li Chen - China Healthcare&LifeScience Review 2024
Focus Us
Copyright © 2025 Hua Medicine (Shanghai) Co., Ltd. 互联网药品信息服务资格证书编号: （沪）-非经营-2022-0079
沪ICP备14036654号-1
沪公网安备 31011502013809号 Privacy Statement Terms of Use
沪ICP备14036654号-1
沪公网安备 31011502013809号 Privacy Statement Terms of Use
Search
How we use cookies
Hua Medicine uses cookies to enable and improve the use of the website. By continuing to use the site, you consent to the use of these cookies. To learn more about cookies, please read our privacy statement.
Accept
x